Clinical trial / 2017
Resveratrol supplementation for 16 weeks did not improve metabolic syndrome markers and high doses increased total and LDL cholesterol.
A 16-week randomized, placebo-controlled, double-blind trial investigated daily oral supplementation with 1000 mg resveratrol (RSVhigh), 150 mg resveratrol, or placebo in 74 middle-aged men with metabolic syndrome. Resveratrol did not alter circulating hs-CRP, interleukin 6, soluble urokinase plasminogen activator receptor, or inflammatory gene expression in muscle and adipose tissues, and showed no effect on blood pressure, body composition, or glucose and lipid metabolism. However, RSVhigh treatment significantly increased total cholesterol (P < 0.002), LDL cholesterol (P < 0.006), and fructosamine (P < 0.013) compared with placebo.
- Study type
- Randomized, placebo-controlled, double-blind parallel trial
- Who was studied
- 74 middle-aged men with metabolic syndrome (66 completed)
- What was measured
- Inflammatory markers, circulating lipids, glucose metabolism, and body composition
THE PAPER
No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial.
Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL, Richelsen B, Pedersen SB. J Clin Endocrinol Metab, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.